Market research
IKNA Ikena Oncology Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 719M
- P/E ratio
- Not available
- Analyst target
- 276.0001
- Dividend yield
- Not available
- Beta
- 0.5
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US45175G1085
- Market cap
- 719M
- P/E ratio
- Not available
- Analyst target
- 276.0001
- Dividend yield
- Not available
- Beta
- 0.5
About
About Ikena Oncology Inc
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. As of July 25, 2025, Ikena Oncology, Inc. was acquired by Inmagene Biopharmaceuticals Co. Ltd.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the IKNA discussion.
5 years, 4 months ago
From a valuation standpoint, the stock is 97.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 39.6.
Based on the above factors, Ikena Oncology, Inc. Common Stock gets an overall score of 1/5.